Diazald-d3
CAS: 42366-72-3
Rif. 3D-SBA36672
1g | Fuori produzione | ||
10mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione | ||
250mg | Fuori produzione | ||
500mg | Fuori produzione |
Informazioni sul prodotto
- 4-Methyl-N-(methyl-d<sub>3</sub>)-N-nitrosobenzenesulfonamide
- Benzenesulfonamide, 4-methyl-N-(methyl-d<sub>3</sub>)-N-nitroso-
- Diazald(R)-N-Methyl-D3
- Diazald-N-Methyl-D3, 98 Atom % D
- Diazald?N-methyl-d3
- N-Methyl-D3-N-Nitroso-P-Toluenesulfonamide
- N-Methyl-N-Nitroso-P-Toluenesulfonamide (N-Methyl-D3)
- p-Toluenesulfonamide, N-methyl-d<sub>3</sub>-N-nitroso-
- 4-Methyl-N-(methyl-d3)-N-nitrosobenzenesulfonamide
- p-Toluenesulfonamide, N-methyl-d3-N-nitroso-
- Vedi altri sinonimi
- Benzenesulfonamide, 4-methyl-N-(methyl-d3)-N-nitroso-
Diazald-d3 is a potent inhibitor of cancer cell growth and a promising medicinal compound for the treatment of various types of cancer. It targets human kinases involved in the regulation of the cell cycle, which are often overexpressed in tumor cells. Diazald-d3 has been shown to induce apoptosis and inhibit proliferation in several cancer cell lines, making it a potential anticancer agent. In addition, recent studies suggest that Diazald-d3 can be effectively delivered to cancer cells using nanoparticles, increasing its therapeutic potential. With its ability to target key proteins involved in cancer development and progression, Diazald-d3 represents a promising avenue for the development of novel cancer therapies.